Why is NeuroPace stock plummeting 40% today?
NeuroPace (NPCE) stock fell 38.3% to $7.42 after reporting Q3 2026 revenue of $23.1M, missing estimates of $27.1M. The company cut its full-year 2026 revenue outlook to $91–92M from $99.5–101.5M, citing sales force disruptions. Leerink downgraded NPCE to Market Perform with a $7 target, while KeyBanc reduced its target to $14. Insider selling and a rate-sensitive macro environment added to the decline.
How this was made
The 30-second read
Why it matters
The earnings miss and downgrade caused a sharp intraday drop, signaling heightened risk for the stock.
Market read
The stock's steep decline underscores the sensitivity of small‑cap med‑tech names to earnings surprises.
What to watch
Potential upcoming clinical milestones could mitigate short‑term pain.
Background
NeuroPace reported Q3 2026 results, missing revenue estimates and cutting full‑year guidance.
Ticker impact
Q3 2026 revenue miss and full-year guidance cut triggered a 38% pre‑open plunge.
likely pressure as the market prices in the guidance reduction and analyst downgrade
The earnings miss, guidance cut, and downgrade are fresh, material facts for a micro‑cap growth name.
Market effects
Highlights weakness in the neuro‑technology sector and may weigh on similar small‑cap med‑tech stocks.
Limited to U.S. markets; broader indices rose modestly, offering little offset.
Minimal global impact beyond niche investors.
Counterpoint
If the company can stabilize sales force execution, the price may be oversold.
Key entities
- companyNeuroPace
Developer of responsive neurostimulation devices.
- analystLeerink
Downgraded NPCE to Market Perform with a $7 target.
- analystKeyBanc
Trimmed price target to $14 while keeping Overweight.


